6.10
-0.27 (-4.24%)
| Penutupan Terdahulu | 6.37 |
| Buka | 6.01 |
| Jumlah Dagangan | 241,807 |
| Purata Dagangan (3B) | 280,230 |
| Modal Pasaran | 129,285,224 |
| Harga / Jualan (P/S) | 1.97 |
| Harga / Buku (P/B) | 1.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Feb 2025 - 10 Feb 2025 |
| Margin Keuntungan | -160.27% |
| Margin Operasi (TTM) | -134.58% |
| EPS Cair (TTM) | -5.48 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -4.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 151.88% |
| Nisbah Semasa (MRQ) | 4.92 |
| Aliran Tunai Operasi (OCF TTM) | -89.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -63.27 M |
| Pulangan Atas Aset (ROA TTM) | -17.18% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Enanta Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.88 |
|
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.09% |
| % Dimiliki oleh Institusi | 100.66% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Krensavage Asset Management, Llc | 30 Sep 2024 | 1,498,074 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 21.00 (JMP Securities, 244.26%) | Beli |
| Median | 20.00 (227.87%) | |
| Rendah | 18.00 (HC Wainwright & Co., 195.08%) | Beli |
| Purata | 19.67 (222.46%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 7.74 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Dec 2024 | 18.00 (195.08%) | Beli | 6.10 |
| 10 Oct 2024 | 27.00 (342.62%) | Beli | 10.63 | |
| Baird | 26 Nov 2024 | 20.00 (227.87%) | Beli | 8.56 |
| JMP Securities | 26 Nov 2024 | 21.00 (244.26%) | Beli | 8.56 |
| 09 Oct 2024 | 22.00 (260.66%) | Beli | 10.71 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |